Search - tctmd.com

Displaying 101 - 120 of 127

Sort: Relevancy | Date

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

Presentation TCT 2012

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

Presenter: Clemens von Birgelen

October 23, 2012

Presentation TCT 2012

Everolimus-Eluting Stents: SPIRIT and PLATINUM Update

Presenter: Gregg Stone

October 22, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Conference News TCT 2012

New Results from SYNTAX, SPIRIT Trials Presented

October 22, 2012

News Conference News TCT 2012

Meta-Analyses Show Improved Outcomes with DES vs. BMS

October 22, 2012

Presentation TCT 2012

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Presenter: Emmanouil Brilakis

October 22, 2012

Presentation TCT 2012

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Presenter: SunWon Kim, Seung Woon Rha, Byoung Geol Choi, Amro Elnagar, Sung Il Im, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

January 03, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Outcomes Following Unprotected Left Main Stenting with Everolimus-Eluting Stents: the Milan Experience.

Presenter: Gill L. Buchanan, Alfonso Ielasi, Alaide Chieffo, Matteo Montorfano, Cosmo Godino, Azeem Latib, Mauro Carlino, Antonio Colombo

January 03, 2012

Presentation TCT 2012

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Presenter: Kyounghoon Lee, Tae Hoon Ahn, Soon Yong Suh, Woong Chol Kang, Seung Hwan Han, Eak Kyun Shin

January 03, 2012

Presentation TCT 2012

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

Presenter: Jose M. De la Torre Hernandez, Dae-Hyun Lee, Tamara Garcia Camarero, Piedad Lerena, Gonzalo Martin Gorria, Fermin Sainz Laso, Javier Zueco

January 03, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

Advertisement

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

Everolimus-Eluting Stents: SPIRIT and PLATINUM Update

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

New Results from SYNTAX, SPIRIT Trials Presented

Meta-Analyses Show Improved Outcomes with DES vs. BMS

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Outcomes Following Unprotected Left Main Stenting with Everolimus-Eluting Stents: the Milan Experience.

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Preclinical Results Promising for Combo Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content